RESUMEN
Recent case reports of ovarian cancer associated with infertility treatment raise the question of a possible etiopathogenetic role of fertility drugs in ovarian cancer. In this paper, the possible relationship between infertility treatment and ovarian cancer is reviewed with respect to the epidemiological and pathogenetic profiles of ovarian cancer and the potential risk factors associated with fertility drugs; a case report review and a critical reappraisal are also provided within this article. Currently available data in the literature, from epidemiological studies and case reports, suggest that a direct causal effect of infertility treatment on ovarian cancer seems unlikely. Since infertile women are likely to have a higher risk for the development of ovarian cancer, and the role of fertility drugs in the etiopathogenesis of ovarian carcinoma is not established, a close clinical examination of infertile patients before, during and after infertility treatment is recommended. Moreover, further investigation is required to resolve the question of the possible association between fertility drugs and ovarian cancer through large prospective epidemiological or retrospective case-control studies.
Asunto(s)
Fármacos para la Fertilidad Femenina/efectos adversos , Neoplasias Ováricas/inducido químicamente , Adulto , Femenino , Humanos , Neoplasias Ováricas/epidemiología , Inducción de la OvulaciónAsunto(s)
Fertilización In Vitro , Hormona del Crecimiento/uso terapéutico , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Síndrome del Ovario Poliquístico/metabolismo , Animales , Aromatasa/efectos de los fármacos , Aromatasa/metabolismo , Clomifeno/uso terapéutico , Quimioterapia Combinada , Estradiol/metabolismo , Femenino , Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/uso terapéutico , Gonadotropinas/uso terapéutico , Células de la Granulosa/efectos de los fármacos , Células de la Granulosa/metabolismo , Humanos , Factor I del Crecimiento Similar a la Insulina/uso terapéutico , Menotropinas/uso terapéutico , Síndrome de Hiperestimulación Ovárica/complicaciones , Síndrome de Hiperestimulación Ovárica/tratamiento farmacológico , Ovario/efectos de los fármacos , Ovario/metabolismo , Ovulación/efectos de los fármacos , Síndrome del Ovario Poliquístico/complicaciones , Embarazo , RatasAsunto(s)
Gonadotropinas Hipofisarias/uso terapéutico , Hormona de Crecimiento Humana/uso terapéutico , Inducción de la Ovulación/métodos , Animales , Ensayos Clínicos como Asunto , Femenino , Gonadotropinas Hipofisarias/administración & dosificación , Hormona Liberadora de Hormona del Crecimiento/administración & dosificación , Hormona de Crecimiento Humana/administración & dosificación , Hormona de Crecimiento Humana/fisiología , Humanos , Ovario/fisiologíaRESUMEN
The present study investigated the effect of allopregnanolone (5 alpha-pregnan-3 alpha-ol-20-one) or of passive immunoneutralization of brain allopregnanolone, the most potent steroid produced by neurons, on ovulation rate and sexual behavior in female rats. Allopregnanolone was injected intracerebroventricularly in rats on diestrus and proestrus and tests were done on estrus. The intracerebroventricular injection of allopregnanolone significantly decreased the number of oocytes collected on estrus (p < 0.01). To support a physiological involvement, antiserum to allopregnanolone was injected centrally to block the activity of the endogenous neurosteroid. When administered on diestrus and proestrus or only on proestrus, the antiserum was shown to be correlated with a significant increase (p < 0.01) in oocytes retrieved on estrus. In female rats treated with antiserum to allopregnanolone, the lordosis intensity was augmented significantly as compared to controls. Finally, the possible changes of medial basal hypothalamus concentration of allopregnanolone throughout the estrous cycle and at the time of ovulation were investigated. Hypothalamic extracts were eluted on high-pressure liquid chromatography and allopregnanolone concentration was measured by radioimmunoassay. Brain cortex was used as control tissue. Hypothalamic allopregnanolone concentration on proestrus morning and afternoon was found to be significantly lower than in the remaining phases of the estrous cycle (p < 0.01), while no significant changes were observed in brain cortex concentration of allopregnanolone. The present results suggest that hypothalamic allopregnanolone may be involved in the mechanism of ovulation, affecting hormonal and behavioral events.
Asunto(s)
Pregnanolona/fisiología , Reproducción/fisiología , Animales , Encéfalo/metabolismo , Diestro , Estro , Femenino , Hipotálamo/metabolismo , Inmunización Pasiva , Inyecciones Intraventriculares , Oocitos/efectos de los fármacos , Ovulación/efectos de los fármacos , Postura , Pregnanolona/inmunología , Pregnanolona/farmacología , Proestro , Ratas , Conducta Sexual Animal/efectos de los fármacosRESUMEN
Human placenta produces a large variety of bioactive substances with endocrine and neural competence: pituitary and gonadal hormones, hypothalamic-like releasing or inhibiting hormones, growth factors, cytokines and neuropeptides. The most recent findings indicate that locally produced hormones regulate the secretion of other placental hormones supporting a paracrine/autocrine regulation. In placental endocrinology, a particular relevance is played by steroid hormones. In fact, a specific gonadotropin-releasing hormone (GnRH)-human chorionic gonadotropin (hCG) regulation of placental steroidogenesis has been proposed as a placental internal regulatory system acting on steroids production from human placenta. In addition, activin and inhibin have been proposed as further regulatory substances of the synthesis and secretion of steroids; the addition of activin A to placental culture augments GnRH, hCG and progesterone, and this effect can be significantly reduced by the addition of inhibins. Finally, a steroid-steroid interaction is suggested by the evidence that placental estrogen has a positive role in the regulation of progesterone biosynthesis. Other steroid-protein interactions have been observed in human placenta. In fact, recent data indicate that progesterone inhibits placental corticotropin-releasing factor (CRF) and estrogens act on placental conversion of cortisol to cortisone, activating cortisol secretion by the fetal adrenal and enhancing fetal adrenal function with advancing gestation.